Aktis Oncology, Inc. (AKTS)
Nasdaq: AKTS · Pharmaceutical Preparations · filing with the SEC since 2024
Who runs Aktis Oncology, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Roden Matthew
President and CEO. First filing Jan 2026, latest Jan 8, 2026, 0 filings in all.
Officers reporting now
5
of 14 people with a filing in the last fifteen months
Directors reporting now
9
14 people on the record since 2026
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Czibere Akos | Chief Medical Officer | Jan 2026 | Sep 24, 2026 | 5 · $1.6M |
| Ron-Bigger Shulamit | Chief Operating Officer | Jan 2026 | Jul 10, 2026 | 3 · $1.4M |
| Roden Matthew | President and CEO | Jan 2026 | Jan 8, 2026 | none |
| Kuvalanka Kyle D. | Chief Financial Officer | Jan 2026 | Jan 8, 2026 | none |
| Feldman Paul L | Chief Scientific Officer | Jan 2026 | Jan 8, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Herrmann Ken | director | Jan 2026 | Jul 21, 2026 | 3 · $200,000 |
| Gormley Glenn | director | Apr 2026 | Apr 16, 2026 | none |
| Foley Todd | director | Jan 2026 | Jan 14, 2026 | none |
| Ecor1 Capital, LLC | director | Jan 2026 | Jan 12, 2026 | none |
| Kim Helen Susan | director | Jan 2026 | Jan 12, 2026 | none |
| Nodelman Oleg | director | Jan 2026 | Jan 12, 2026 | none |
| Segal Lloyd Mitchell | director | Jan 2026 | Jan 12, 2026 | none |
| Sherman Michael A. | director | Jan 2026 | Jan 8, 2026 | none |
| Thistle Mary | director | Jan 2026 | Jan 8, 2026 | none |
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Eli Lilly & Co | 10% owner | Jan 2026 | Jan 15, 2026 | none |
| Evnin Luke | 10% owner | Jan 2026 | Jan 14, 2026 | none |
| Gadicke Ansbert | 10% owner | Jan 2026 | Jan 14, 2026 | none |
| Mpm Asset Management Investors Bv2018 LLC | 10% owner | Jan 2026 | Jan 14, 2026 | none |
| Mpm Asset Management LLC | 10% owner | Jan 2026 | Jan 14, 2026 | none |
| Mpm Bioventures 2018 (B), L.P. | 10% owner | Jan 2026 | Jan 14, 2026 | none |
| Mpm Bioventures 2018 Gp LLC | 10% owner | Jan 2026 | Jan 14, 2026 | none |
| Mpm Bioventures 2018 LLC | 10% owner | Jan 2026 | Jan 14, 2026 | none |
| Mpm Bioventures 2018, L.P. | 10% owner | Jan 2026 | Jan 14, 2026 | none |
| Mpm Oncology Innovations Fund Gp LLC | 10% owner | Jan 2026 | Jan 14, 2026 | none |
| Mpm Oncology Innovations Fund LP | 10% owner | Jan 2026 | Jan 14, 2026 | none |
| Oncology Impact Private Investment Fund 2, L.P. | 10% owner | Jan 2026 | Jan 14, 2026 | none |
| Vida Ventures II-A, LLC | 10% owner | Jan 2026 | Jan 12, 2026 | none |
| Vida Ventures II, LLC | 10% owner | Jan 2026 | Jan 12, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.